机构：[1]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[2]Canc Hosp, Chinese Acad Med Sci, Shenzhen Ctr, Shenzhen, Peoples R China[3]Harbin Med Univ, Tumor Hosp, Harbin, Peoples R China[4]Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China[5]Sichuan Canc Hosp, Chengdu, Peoples R China四川省肿瘤医院[6]Peking Union Med Coll Hosp, Beijing, Peoples R China[7]Zhejiang Taizhou Hosp, Taizhou, Peoples R China台州恩泽医疗中心台州医院[8]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
第一作者机构：[1]Zhejiang Canc Hosp, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Huang Z.,Chang J.,Yu Y.,et al.ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2022,17(9):S352-S353.doi:10.1016/j.jtho.2022.07.605.
APA：
Huang, Z.,Chang, J.,Yu, Y.,Liu, C.,Li, J....&Fan, Y..(2022).ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC.JOURNAL OF THORACIC ONCOLOGY,17,(9)
MLA：
Huang, Z.,et al."ML40471: Preliminary Analysis of Atezolizumab in Previously Treated Patients With Locally Advanced or Metastatic NSCLC".JOURNAL OF THORACIC ONCOLOGY 17..9(2022):S352-S353
医学